- Home
- MVIS vs ATAI Comparison
MVIS vs ATAI Comparison
Compare MVIS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- ATAI
- Stock Information
- Founded
- MVIS 1993
- ATAI 2018
- Country
- MVIS United States
- ATAI Germany
- Employees
- MVIS N/A
- ATAI N/A
- Industry
- MVIS Industrial Machinery/Components
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- MVIS Technology
- ATAI Health Care
- Exchange
- MVIS Nasdaq
- ATAI Nasdaq
- Market Cap
- MVIS 308.8M
- ATAI 291.5M
- IPO Year
- MVIS 1996
- ATAI 2021
- Fundamental
- Price
- MVIS $1.19
- ATAI $1.24
- Analyst Decision
- MVIS Buy
- ATAI Strong Buy
- Analyst Count
- MVIS 4
- ATAI 4
- Target Price
- MVIS $2.67
- ATAI $9.00
- AVG Volume (30 Days)
- MVIS 5.1M
- ATAI 1.7M
- Earning Date
- MVIS 03-26-2025
- ATAI 03-17-2025
- Dividend Yield
- MVIS N/A
- ATAI N/A
- EPS Growth
- MVIS N/A
- ATAI N/A
- EPS
- MVIS N/A
- ATAI N/A
- Revenue
- MVIS $4,696,000.00
- ATAI $308,000.00
- Revenue This Year
- MVIS $486.46
- ATAI N/A
- Revenue Next Year
- MVIS $139.22
- ATAI $20.00
- P/E Ratio
- MVIS N/A
- ATAI N/A
- Revenue Growth
- MVIS N/A
- ATAI N/A
- 52 Week Low
- MVIS $0.80
- ATAI $1.03
- 52 Week High
- MVIS $1.95
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- MVIS 43.82
- ATAI 36.74
- Support Level
- MVIS $1.15
- ATAI $1.42
- Resistance Level
- MVIS $1.69
- ATAI $1.58
- Average True Range (ATR)
- MVIS 0.13
- ATAI 0.12
- MACD
- MVIS -0.01
- ATAI -0.00
- Stochastic Oscillator
- MVIS 19.35
- ATAI 4.55
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.